| Literature DB >> 20643554 |
William Engen1, Terrence E O'Brien, Brendan Kelly, Jacinda Do, Liezel Rillera, Lance K Stapleton, Jack F Youngren, Marc O Anderson.
Abstract
The insulin-like growth factor receptor (IGF-1R) is a receptor tyrosine kinase (RTK) involved in all stages of the development and propagation of breast and other cancers. The inhibition of IGF-1R by small molecules remains a promising strategy to treat cancer. Herein, we explore SAR around previously characterized lead compound (1), which is an aryl-heteroaryl urea (AHU) consisting of 4-aminoquinaldine and a substituted aromatic ring system. A library of novel AHU compounds was prepared based on derivatives of the 4-aminoquinoline heterocycle (including various 2-substituted derivatives, and naphthyridines). The compounds were screened for in vitro inhibitory activity against IGF-1R, and several compounds with improved activity (3-5 microM) were identified. Furthermore, a computational docking study was performed, which identifies a fairly consistent lowest energy mode of binding for the more-active set of inhibitors in this series, while the less-active inhibitors do not adopt a consistent mode of binding. Copyright 2010 Elsevier Ltd. All rights reserved.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20643554 PMCID: PMC2918655 DOI: 10.1016/j.bmc.2010.06.071
Source DB: PubMed Journal: Bioorg Med Chem ISSN: 0968-0896 Impact factor: 3.641